Cardiol Therapeutics Inc.
CRDL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $62 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $187 | $162 | $174 |
| Gross Profit | $0 | -$187 | -$162 | -$112 |
| % Margin | – | – | – | -179.9% |
| R&D Expenses | $14,012 | $10,732 | $13,988 | $8,594 |
| G&A Expenses | $26,265 | $0 | $0 | $0 |
| SG&A Expenses | $26,265 | $11,554 | $16,343 | $21,862 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $40,277 | $22,286 | $30,331 | $30,456 |
| Operating Income | -$40,277 | -$22,473 | -$30,493 | -$30,568 |
| % Margin | – | – | – | -49,092.4% |
| Other Income/Exp. Net | $3,599 | $1,250 | $7,676 | $5,555 |
| Pre-Tax Income | -$36,677 | -$21,223 | -$22,818 | -$25,013 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36,677 | -$21,223 | -$22,818 | -$25,013 |
| % Margin | – | – | – | -40,170.9% |
| EPS | -0.51 | -0.44 | -0.49 | -0.73 |
| % Growth | -15.9% | 10.2% | 32.9% | – |
| EPS Diluted | -0.51 | -0.44 | -0.49 | -0.73 |
| Weighted Avg Shares Out | 71,567 | 64,463 | 62,506 | 43,222 |
| Weighted Avg Shares Out Dil | 71,568 | 64,463 | 62,506 | 43,223 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,193 | $2,038 | $1,238 | $106 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $162 | $187 | $162 | $174 |
| EBITDA | -$40,115 | -$21,035 | -$22,655 | -$24,839 |
| % Margin | – | – | – | -39,891% |